MindWalk Holdings (HYFT) Return on Capital Employed (2021 - 2026)
MindWalk Holdings (HYFT) posted quarterly Return on Capital Employed of 17.05% for Q2 2026, up 1405312.0% year-over-year from N/an in Q2 2025, and down 18.05% quarter-over-quarter from 14.44% in Q1 2026.
MindWalk Holdings (HYFT) Return on Capital Employed (2021 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Return on Capital Employed for 6 consecutive years, with 17.05% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed rose 1405312.0% year-over-year to 17.05%; the TTM figure through Apr 2026 stood at 17.05% (up 1405312.0% YoY), while the FY2026 annual figure was 0.14%, down 6.0% from the prior year.
- Return on Capital Employed fell to 17.05% in Q2 2026 per HYFT's latest filing, from 14.44% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 28.12% in Q1 2024 and bottomed at 14070.17% in Q2 2025.
- Historically, Return on Capital Employed has averaged 2544.44% across 5 years, with a median of 10.89% in 2025.
- Annual changes were most pronounced in 2025 — Return on Capital Employed sank 1402829 bps — and 2026, when it surged 1405312 bps.
- MindWalk Holdings' Return on Capital Employed stood at 5.99% in 2022, then surged by 533 bps to 25.9% in 2023, then slumped by 40162 bps to 10374.54% in 2024, then soared by 100 bps to 9.83% in 2025, then sank by 74 bps to 17.05% in 2026.
- Business Quant data shows HYFT's Return on Capital Employed at 17.05% in Q2 2026, 14.44% in Q1 2026, and 9.83% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -36.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -17.05% |
| Jan 31, 2026 | -14.44% |
| Oct 31, 2025 | -9.83% |
| Jul 31, 2025 | -16.30% |
| Apr 30, 2025 | -14,070.17% |
| Jan 31, 2025 | -11,290.10% |
| Oct 31, 2024 | -10,374.54% |
| Jul 31, 2024 | -10,047.74% |
| Apr 30, 2024 | -41.88% |
| Jan 31, 2024 | 28.12% |
| Oct 31, 2023 | 25.90% |
| Jul 31, 2023 | 25.10% |
| Apr 30, 2023 | 24.04% |
| Jan 31, 2023 | -11.96% |
| Oct 31, 2022 | -5.99% |
| Jul 31, 2022 | -5.32% |
| Apr 30, 2022 | -6.54% |
| Jan 31, 2022 | 8.77% |
| Oct 31, 2021 | 5.85% |
| Jul 31, 2021 | 1.85% |